Intact Therapeutics

Intact Therapeutics is developing smart gels for local drug delivery to the gut. Our first target is ulcerative colitis, a form of inflammatory bowel disease that affects millions worldwide. Our proprietary gel technology enables significantly higher localized concentrations of drug and minimizes systemic exposure, all while improving patient comfort and ease of use. We have completed preclinical validation studies and first-in-human pilot studies at Stanford, with very encouraging results in efficacy and patient comfort. Our platform can address a wide range of digestive diseases totaling an over $4B market opportunity.